126 results about "Therapy eye" patented technology

An ophthalmic lens configured to correct and / or treat at least one condition of the eye (e.g., presbyopia, myopia, hyperopia, astigmatism, binocular vision disorders, night vision image quality, and / or visual fatigue syndrome) comprising: a base power profile; and at least one pulse selected to modify the base power profile.

The invention provides methods of treating an eye disorder and compositions for use therein, the methods comprising applying a crosslinkable liquid composition onto an anterior corneal surface of said eye using a mold; crosslinking the crosslinkable liquid composition on the anterior corneal surface of the eye, thereby obtaining a crosslinked composition on the anterior corneal surface of the eye; and correcting the curvature of the crosslinked composition.

Transcorneal and fiberoptic laser delivery systems and methods for the treatment of eye diseases wherein energy is delivered by wavelengths transparent to the cornea to effect target tissues in the eye for the control of intraocular pressure in diseases such as glaucoma by delivery systems both external to and within ocular tissues. External delivery may be affected under gonioscopic control. Internal delivery may be controlled endoscopically or fiberoptically, both systems utilizing femtosecond laser energy to excise ocular tissue. The femtosecond light energy is delivered to the target tissues to be treated to effect precisely controlled photodisruption to enable portals for the outflow of aqueous fluid in the case of glaucoma in a manner which minimizes target tissue healing responses, inflammation and scarring.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

A light based system for treating an eye includes a mask that is configured for positioning on the eye and a light source that is configured to deliver therapeutic light. The mask has an inner surface that is positionable against the eye and an outer surface that is opposite the inner surface. The mask is optically opaque to prevent transmission of light through the mask and the mask includes at least one transparent opening that allows transmission of light through the mask to target tissue of the eye posterior the transparent opening. The light source is positioned relative to the mask so that the delivered therapeutic light irradiates at least a portion of the mask and the transparent opening. Therapeutic light traverses through the transparent opening to the target tissue positioned posterior the transparent opening.

The present application relates to an ophthalmic preparation and use thereof. Specifically, the present application relates to an ophthalmic preparation of pilocarpine and use thereof for treating eye diseases. The ophthalmic preparation of pilocarpine provided by the present application has the beneficial effects of good stability and less eye irritation.

An implant device for an eye disease to be inserted into an eyeball may include: a tube having one end to be inserted into an anterior chamber of the eyeball, the tube comprising a hollow portion through which aqueous humor is drained; and a ripcord inserted into the hollow portion of the tube to control an amount of aqueous humor drainage through the tube. In the implant device, an inner diameter of the tube and a diameter of the ripcord are determined so that pressure formed in the anterior chamber of the eyeball when the tube is inserted into the anterior chamber of the eyeball is within a preset pressure range. The pressure formed in an anterior chamber to an optimal range through an appropriate combination of the tube and the ripcord inserted into the tube.

In certain embodiments, an ophthalmic laser surgical system for treating a target tissue in an eye includes a target detection system and a laser device. The target tissue has an optical breakdown threshold. The target detection system directs detection beams along a detection beam path towards the target tissue in a vitreous of the eye, and determines a location of the target tissue within the vitreous. The laser device includes a femtosecond laser that generates subthreshold laser pulses that have a pulse energy below the optical breakdown threshold of the tissue. The laser device directs a laser beam comprising the subthreshold laser pulses along a laser beam path towards the target tissue.

System and method for using in treatment of an opacity within an eye are presented, the system comprising an input utility configured to receive input data comprising image data of the eye being indicative of a convergence spot of first and second aiming beams entering the eye and converging at location of an opacity within the eye, and of first and second spots formed on the retina by respectively the first and second aiming beams; a processing utility configured to process the input data, the processing comprises processing the image data and determining an inter-spot distance between the first and second spots formed on the retina, and utilizing the inter-spot distance and a model of the eye and determining a first distance between the opacity and the retina and a second distance between the opacity and the crystalline lens of the eye; and an output utility configured and operable to generate output data indicative of opacity treatment recommendation based on the first and second distances.

The present disclosure relates to intraocular implants for treating a condition of the eye, wherein the implant is configured to deliver a drug to the eye. The present disclosure also relates to methods of treating a condition of the eye by delivering a drug from intraocular implants to the posterior chamber (e.g., sulcus), iridocorneal angle, sclera, cornea, limbus, and vitreous.

An ab externo automated laser treatment system for treating an eye in a subject, includes a non-contact laser source configured to generate a laser beam having at least one wavelength to treat the eye by directing the laser beam from a location spaced from the eye, wherein the at least one wavelength is a near-infrared wavelength in the range of about 0.5-2.2 μm, a laser scanner optically coupled to the non-contact laser source to receive the laser beam from the non-contact laser source and to scan the laser beam relative to the eye, and a processor, and memory including stored computer-readable instructions that, responsive to execution by the processor, cause the laser treatment system to direct the laser beam to a plurality of trans-scleral treatment locations to be irradiated in a predetermined treatment pattern on an external surface of the eye, wherein the trans-scleral treatment locations are 0-4 mm posterior to the corneolimbal junction, and wherein the laser beam is repetitively directed to the same irradiated trans-scleral treatment locations on the surface of the eye, and the trans-scleral treatment locations are irradiated at intervals sufficient to induce protective thermal preconditioning and therapeutic bio-stimulation of one or more of the trabecular meshwork and / or ciliary body without photocoagulation of the tissue of the eye. Trans-pupillary systems, patient interfaces, and methods are also disclosed.

To provide ophthalmic devices and methods for treating glaucoma, ocular hypertension (OHT), and other diseases. [Solution] The system (20) comprises a radiation source (48) and a controller (44), the controller being configured to: display a live sequence of images of the patient's (22) eye (25); while displaying the sequence of images of the eye, to direct the radiation source to irradiate the eye with one or more targeting beams (84) visible in the images; after directing the targeting beams to the eye with the radiation source, to receive confirmation input from the user; and in response to receiving confirmation input, to treat the eye by directing the radiation source to irradiate each target area of ​​the eye with multiple treatment beams. Other embodiments are also described.

This application relates to direct selective laser trabeculoplasty. The application relates to a system (20) including a radiation source (48) and a controller (44) configured to display a real-time image sequence of a patient's (22) eye (25), while displaying the image sequence, to irradiate the eye with one or more aiming beams (84) visible in the images, to receive confirmation input from a user after irradiating the eye with the aiming beams, and to treat the eye by irradiating a corresponding target area of ​​the eye with the radiation source using multiple treatment beams in response to receiving the confirmation input. Other embodiments are also described.

The invention relates to an ophthalmic surgical system (2) for treating an eye, comprising a console (1) with a cassette holder (3) and a cassette (6). The cassette (6) has at least one first surface design element (8). The cassette holder (3) has at least one second surface design element (20) and is configured to hold the cassette (6) in a predetermined position within the cassette holder (3) when the first surface design element (8) and the second surface design element (20) are positioned in an interlocking manner. The first surface design element (8) and / or the second surface design element (20) have at least one change in cross-sectional area in a direction transverse to a surface (9, 21) on which the respective surface design element (8, 20) is arranged.Only if the surface design elements (8, 20) are designed to fit each other, can the first surface design element (8) and the second surface design element (20) be positioned interlocking at all.

The invention belongs to the technical field of medicines, and particularly relates to application of IR808 in preparation of a medicine for treating eye bacterial infection diseases. According to the invention, IR808 is taken as a photosensitizer, laser irradiation is combined, and singlet oxygen generated by IR808 is utilized to play an antibacterial role. The developed eye drops, intraocular injections, sustained-release nanoparticles and gel preparations are designed aiming at the eye environment, and have good biocompatibility and stability. The treatment scheme in an animal model proves that pathogens including drug-resistant bacteria can be efficiently killed at low concentration, intraocular tissue damage caused by infection can be effectively relieved, and observable toxicity to intraocular cells and the whole body of an experimental animal is not shown. The invention provides a novel effective method for treating bacterial infection of eyes, especially for solving the drug resistance of antibiotics and improving the treatment safety.

The present disclosure provides inhibitors of one or more subunits of polycomb repressive complex 2 (PRC2) for use in the prevention or the treatment of an eye disorder in a subject in need thereof and methods for treating an eye disorder, e.g. non-cancer disorders, in a subject using a therapeutically effective amount of one or more inhibitors of a subunit of polycomb repressive complex 2 (PRC2).In certain embodiments of the methods of the disclosure, the eye disorders are characterized by degeneration or cell death of retinal neurons.In certain embodiments of the methods of the disclosure, the subunit of PRC2 is EZH1 or EZH2, and the inhibitor is an inhibitor of H3K27 trimethylation.

Methods of treating an eye are provided that entail partially penetrating the sclera and delivering light energy from an optical fiber within the penetration to treat the a target tissue in the eye, for example, to coagulate vasculature underlying the sclera within a planned incision area. Also provided are treatment probes for treating an eye of a patient includes an elongate body that defines a handle and an advanceable penetrating member and optical fiber housed within the elongate body. The probe is configured to advance the penetrating member so as to penetrate the sclera, only partially, and advance the treatment fiber into the penetration to deliver treatment light energy to coagulate the vasculature underlying the sclera. The probe can include one or more penetrating members and corresponding optical fibers to form one or more penetrations concurrently within the planned incision area.

In certain embodiments, an ophthalmic laser surgical system for treating a floater in a vitreous of an eye includes a floater detection system, a laser device, and a computer. The floater detection system determines the location of the floater in the vitreous of the eye. The laser device directs a laser beam along a laser beam path towards the floater. The computer accesses a three-dimensional scan pattern for the laser beam that yields a three-dimensional pulse pattern of laser pulses. The three-dimensional pulse pattern has a bubble shield pulse pattern at the posterior side of the three-dimensional pulse pattern. The bubble shield pulse pattern forms a bubble shield that reduces laser radiation exposure at a retina of the eye. The computer instructs the laser device to direct the laser beam towards the floater according to the three-dimensional scan pattern.

A method of treating an eye disorder in a patient that may include administering a medicament to the patient with a prefilled syringe, wherein the administration of the medicament with the prefilled syringe is configured to treat the eye disorder and decrease a rate of likelihood of an ocular infection to the patient's eye.

A system for treating clogged glands of the eye includes a heated eye mask, an electrical cord, and a controller. The heated eye mask includes an outer layer of surface material, an inner layer of surface material, and a graphene heating element. The graphene heating element is disposed between the outer and inner layers of surface material in a therapeutic region of the heated eye mask. The therapeutic region of the heated eye mask extends along the Meibomian glands of the eye. The graphene heating element is encapsulated by an electrically insulating cover. A thermally conductive material evenly distributes heat across the therapeutic region of the heated eye mask. The electrical cord provides power to the heated eye mask. The controller is provided on the electrical cord for controlling the heated eye mask to heat to one of at least four pre-set temperature levels.

The invention provides emulsion compositions comprising at least one cannabinoid compound, and methods for making the same. The emulsion compositions are stable, well tolerated and are capable of delivering therapeutically effective amounts of cannabinoids to target sites, including sites on the surface of and / or within an eye. Also provided are methods of using the compositions to provide ocular neuroprotection and / or to treat ophthalmic conditions such as glaucoma.

Methods, systems and apparatuses for delivering electrical or other therapy in the vicinity of the eye. One or more electrodes are positioned on or near the eye, such as contacting the superior or inferior eyelids, on the conjunctiva or medial or lateral canthus, on or inside the nose, or on the forehead. A remote or return electrode is optionally positioned elsewhere on the patient on the torso, neck, back, a limb, an extremity, on the back or side of the head, or near the ear, mandible or temple. A variety of pulse generator positions and support apparatuses are disclosed as well. The pulse generator is used to deliver one or more of therapy or diagnostic electrical pulses to the patient to address a condition of the eye.

The invention discloses a terahertz-based stable tear film treatment ocular surface detection system, which comprises a terahertz emission module, an ocular surface detection module, an intelligent control module, an environment perception module and a man-machine interaction module, and is characterized in that the terahertz emission module is used for emitting frequency-adjustable terahertz waves to the ocular surface so as to adjust the molecular structure and energy of ocular surface water; the ocular surface detection module is used for collecting multiple physiological parameters of the ocular surface in real time. The stable tear film treatment ocular surface detection system based on terahertz realizes ocular surface multi-parameter real-time detection, terahertz wave accurate regulation and control and closed-loop linkage of detection and treatment, has environment self-adaption and personalized optimization capabilities, fundamentally adjusts ocular surface water molecule structure and energy, and improves the treatment efficiency. A tear film is stabilized, and accurate detection and long-acting treatment of ocular surface diseases such as xerophthalmia are realized.

The present invention relates to drug conjugates comprising hyaluronic acid (HA) hydrogel microspheres or pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods of using such conjugates for the treatment of ocular disorders, and methods of making the conjugates.

The invention relates to a method and device for treating eye diseases, and belongs to the field of medical treatment. In order to treat ocular hypertension and glaucoma, a device for reducing intraocular pressure is provided, the device comprising: a plate having a first end and a second end, the plate comprising opposing first and second surfaces wherein the first surface comprises a series of fluid channels, the series of fluid channels are configured in an open cross-network pattern extending from a first end of the plate to a second end of the plate, the width of the first end of the plate being narrower than the width of the second end of the plate to enable the first end of the plate to be inserted into the anterior chamber of the patient, and wherein the second surface comprises a plurality of open cells formed by the fluid channels; a first coating on the first surface, the first coating conforming to a topography of the series of fluid channels, and a second coating on the second surface. The devices described herein can be used to reduce intraocular pressure and treat glaucoma.

The invention relates to an ophthalmic surgical system (1) for treating an eye (2), and to a method. The ophthalmic surgical system (1) comprises a pressure sensor (12) which determines pressure information describing at least a pressure exerted by a treatment fluid on the pressure sensor (12) and, in the event of a handpiece (9) or infusion element at least partially inserted into the eye (2), a pressure exerted on the pressure sensor (12) by an intraocular pressure of the eye (2). A time curve (30) of the pressure information is determined and analysed to ascertain whether a pressure information increase (31) can be detected in which the pressure information increases in stages from a first pressure information (32) to a second pressure information (33), wherein a pressure information difference (34) between the two items of pressure information (32, 33) is greater than a specified minimum value (36). If the pressure information increase (31) has been detected, patient eye height information (38) and / or intraocular pressure information (37) is determined and provided by applying an evaluation algorithm (42) to the first pressure information (32) and / or the second pressure information (33).

A topical composition comprising, as active ingredient, a mixture of hyaluronic acid, trehalose and an extract of roots of Ophiopogon japonicus, for use as soothing and / or moisturizing agent for the eyelids and / or the contour of the eye in a subject with sensitive skin, in particular with blepharitis.

A composition for use in treatment of ocular disorders is provided, comprising human keratinocyte growth factor-2 (hKGF-2) and a stabilizing agent, wherein the stabilizing agent comprises one or more of: 0.1% to 2% (w / v) mannitol or 0.01% to 0.05% (w / v) sodium hyaluronate; 0.1% to 2% (w / v) glycerol; 0.1% to 2% (w / v) trehalose or 0.5% (w / v) human serum albumin; and 0.1% to 2% (w / v) lysine hydrochloride. The compatibility between the hKGF-2 stock solution and pharmaceutical excipients was systematically studied to determine optimal concentration ranges for the stabilizing agent, surfactant, and pH-regulator. Based on these ranges, the denaturation (melting) and aggregation temperatures of hKGF-2 in the solution system were evaluated to establish an optimized formulation, in which the biological activity of hKGF-2 is maintained for an extended period. Compared with existing eye drop formulations, the hKGF-2 eye drops of the present disclosure demonstrate improved efficacy in the treatment of dry eye disease.